Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen et al. · Nature Communications · 2017
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC class I antigen presentation, in 29.4% of patients with progressing disease. In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we find that B2M LOH is enriched threefold in non-responders (~30%) compared to responders (~10%) and associated with poorer overall survival. Loss of both copies of B2M is found only in non-responders. B2M loss is likely a common mechanism of resistance to therapies targeting CTLA4 or PD1.
Cited by 995 works. doi:10.1038/s41467-017-01062-w Open-access PDF
Authors
- Moshe Sade-Feldman
- Yunxin J. Jiao
- Jonathan H. Chen
- Michael S. Rooney
- Michal Barzily-Rokni
- Jean-Pierre Eliane
- Stacey L. Bjorgaard
- Marc R. Hammond
- Hans Vitzthum
- Shauna M. Blackmon
- Dennie Tompers Frederick
- Mehlika H. Hazar-Rethinam
- Brandon Nadres
- Emily E. Van Seventer
- Sachet Ashok Shukla
- Keren Yizhak
- Daniel Rosebrock
- Dimitri G. Livitz
- Viktor A. Adalsteinsson
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Fiji: an open-source platform for biological-image analysis
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- STAR: ultrafast universal RNA-seq aligner
- The blockade of immune checkpoints in cancer immunotherapy
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal